Sulphated sugar alpha-cyclodextrin sulphate, a uniquely potent anti-HIV agent, also exhibits marked synergism with AZT, and Iymphoproliferative activity

被引:24
作者
Anand, R. [1 ]
Nayyar, S. [2 ]
Pitha, J. [3 ]
Merril, C. R. [2 ]
机构
[1] CBER FDA, Lab Retrovirol, Bethesda, MD 20892 USA
[2] NIMH, Lab Biochem Genet, Neurosci Ctr, St Elizabeths Hosp, Washington, DC 20032 USA
[3] NIA, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA
关键词
D O I
10.1177/095632029000100107
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sulphated sugars, alpha-cyclodextrin sulphate (A-CDS), sodium pentosan polysulphate (PPS), and beta-cyclodextrin sulphate (B-CDS) were evaluated for their inhibitory effect on the replication of human immunodeficiency virus (HIV-1) in normal human peripheral blood mononuclear cells (PMNCs). All three drugs had potent anti-HIV activity, A-CDS being the most potent. A-CDS, PPS and B-CDS were also tested for their direct inhibitory effect on reverse transcriptase (RT) in vitro. PPS inhibited the RT reaction at 4.0 mu g ml(-1) and above whereas B-CDS and A-CDS did not. The drugs were not cytotoxic up to 100 mu g ml(-1) and also showed significant Iymphoproliferative activities. PPS and B-CDS exhibited higher Iymphoproliferative activity than A-CDS. A-CDS, B-CDS, and PPS showed profound antiviral synergism with AZT. An additive anti-HIV effect, rather than a synergestic effect, was observed between the sulphated sugars. Thus, these sulphated sugars, because of their nontoxic nature, Iymphoproliferative activity and anti-HIV activity at low concentrations, may be valuable chemotherapeutic agents in the treatment of AIDS. In particular, A-CDS, because of its marked anti-HIV synergism with AZT (Which would lower the required dose of AZT in vivo), could result in an efficacious and essentially nontoxic combination chemotherapy for AIDS.
引用
收藏
页码:41 / 46
页数:6
相关论文
共 32 条
[1]   INTERACTION BETWEEN RIFABUTIN AND HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 - INHIBITION OF REPLICATION, CYTOPATHIC EFFECT, AND REVERSE-TRANSCRIPTASE INVITRO [J].
ANAND, R ;
MOORE, JL ;
CURRAN, JW ;
SRINIVASAN, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :684-688
[2]   BIOLOGICAL AND MOLECULAR CHARACTERIZATION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV-1BR) FROM THE BRAIN OF A PATIENT WITH PROGRESSIVE DEMENTIA [J].
ANAND, R ;
THAYER, R ;
SRINIVASAN, A ;
NAYYAR, S ;
GARDNER, M ;
LUCIW, P ;
DANDEKAR, S .
VIROLOGY, 1989, 168 (01) :79-89
[3]   PENTOSAN POLYSULFATE, A SULFATED OLIGOSACCHARIDE, IS A POTENT AND SELECTIVE ANTI-HIV AGENT INVITRO [J].
BABA, M ;
NAKAJIMA, M ;
SCHOLS, D ;
PAUWELS, R ;
BALZARINI, J ;
DECLERCQ, E .
ANTIVIRAL RESEARCH, 1988, 9 (06) :335-343
[4]   ACTIVITY OF DEXTRAN SULFATE AND OTHER POLYANIONIC POLYSACCHARIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS [J].
BAGASRA, O ;
LISCHNER, HW .
JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (05) :1084-1087
[5]   ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].
BARRESINOUSSI, F ;
CHERMANN, JC ;
REY, F ;
NUGEYRE, MT ;
CHAMARET, S ;
GRUEST, J ;
DAUGUET, C ;
AXLERBLIN, C ;
VEZINETBRUN, F ;
ROUZIOUX, C ;
ROZENBAUM, W ;
MONTAGNIER, L .
SCIENCE, 1983, 220 (4599) :868-871
[6]   GENOMIC DIVERSITY OF THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME RETROVIRUSES IS REFLECTED IN ALTERATION OF ITS TRANSLATIONAL PRODUCTS [J].
DEVARE, SG ;
SRINIVASAN, A ;
BOHAN, CA ;
SPIRA, TJ ;
CURRAN, JW ;
KALYANARAMAN, VS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (15) :5718-5722
[7]   FREQUENT DETECTION AND ISOLATION OF CYTOPATHIC RETROVIRUSES (HTLV-III) FROM PATIENTS WITH AIDS AND AT RISK FOR AIDS [J].
GALLO, RC ;
SALAHUDDIN, SZ ;
POPOVIC, M ;
SHEARER, GM ;
KAPLAN, M ;
HAYNES, BF ;
PALKER, TJ ;
REDFIELD, R ;
OLESKE, J ;
SAFAI, B ;
WHITE, G ;
FOSTER, P ;
MARKHAM, PD .
SCIENCE, 1984, 224 (4648) :500-503
[8]   PNEUMOCYSTIS-CARINII PNEUMONIA AND MUCOSAL CANDIDIASIS IN PREVIOUSLY HEALTHY HOMOSEXUAL MEN - EVIDENCE OF A NEW ACQUIRED CELLULAR IMMUNODEFICIENCY [J].
GOTTLIEB, MS ;
SCHROFF, R ;
SCHANKER, HM ;
WEISMAN, JD ;
FAN, PT ;
WOLF, RA ;
SAXON, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (24) :1425-1431
[9]  
HO DD, 1985, LANCET, V1, P602
[10]  
IRIE T, 1988, INT J PHARM, V43, P41